Hepatitis B virus envelope peptide–HLA-A*02:01 complex

The Hepatitis B virus envelope peptide–HLA-A*02:01 complex is a molecular structure formed when a short peptide derived from the HBV envelope (surface) protein binds to the peptide-binding cleft of the human MHC class I allele HLA-A*02:01. This complex is presented on the surface of infected liver cells, where it is recognized by CD8+ cytotoxic T lymphocytes, triggering an adaptive immune response against HBV. The complex is a major focus of immunological research and is being explored as a therapeutic target in vaccine development and adoptive T cell therapy for chronic hepatitis B infection[2][4][5][7][10]. - Example peptides from HBV Env known to bind HLA-A*02:01 include ILSPFLPLL[10] and GLSPTVWLSV[4]. - The efficiency of peptide presentation, T cell recognition, and mutation-based immune escape are relevant to disease control and therapy in HBV infection[2][5][7]. If further granularity is needed (such as specifying exact peptide sequences), “HBV ENV peptide–HLA-A*02:01 complex” can be subclassified according to the peptide used (e.g., HBs183-91–HLA-A*02:01 for specific studies)[5].

Other names

HBV envelope peptide–HLA-A2 complexHBV Env–HLA-A*02:01 complexHBV Env epitope–HLA-A2 complexHBV S peptide–HLA-A*02:01 complex

Recognition by T cell receptors leads to cytotoxic T lymphocyte activation and lysis of HBV-infected hepatocytes[5][7]. Some therapeutic molecules (e.g., bispecific T cell engagers and ImmTAVs) redirect T cells to target and kill cells presenting the HBV Env–HLA-A*02:01 complex[7]